To Evaluate the Safety and PK Characteristics After Co-administration of JW0104 and C2402 and Administration of JW0105

NCT06754943 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

60

Enrollment

INDUSTRY

Sponsor class

Conditions

Healthy

Interventions

DRUG: Treatment A_Period 1
DRUG: Treatment B_Period 2
DRUG: Treatment A_Period 3
DRUG: Treatment B_Period 4
DRUG: Treatment B_Period 1
DRUG: Treatment A_Period 2
DRUG: Treatment B_Period 3
DRUG: Treatment A_Period 4

Sponsor

JW Pharmaceutical